Introducing Hospira's New CEO And An Ambitious Five-Year Growth Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
With an emphasis on customer needs and relentless execution in highly competitive markets, Hospira,'s new CEO aims to build a top-notch global business focused on offering value propositions that seem to resonate with customers and Wall Street.
You may also be interested in...
Hospira Hinges Emerging Market Success On Scale And Differentiation
Hospira Inc.'s new CEO Michael Ball laid out the company's strategic moves to expand in the fast-growing emerging markets during the company's Sept. 7 Investor's Day conference. The CEO said the U.S.-centric company's future growth hinges on expanding its footprint in emerging markets and launching more products including biosimilars in top pharmaceutical markets in Europe and Japan
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
With patents on blockbuster drugs – including Roche/Biogen Idec Inc.'s Rituxan (rituximab), Amgen Inc./Pfizer Inc.'s Enbrel (etanercept) and Roche's Herceptin (trastuzumab) – due to expire in key markets within the next three years, there's a renewed buzz around biosimilars as industry players seek to grab a share of this multi-billion dollar opportunity.
At-Risk Launches: Three Cases May Determine How Damages Are Calculated
How risky are at-risk launches of generic products?